Raymond James Financial Inc. purchased a new position in Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 247,795 shares of the medical instruments supplier's stock, valued at approximately $32,677,000. Raymond James Financial Inc. owned approximately 4.56% of Mesa Laboratories at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC increased its stake in shares of Mesa Laboratories by 62.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,844 shares of the medical instruments supplier's stock valued at $243,000 after purchasing an additional 706 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in Mesa Laboratories by 3.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 3,394 shares of the medical instruments supplier's stock worth $448,000 after purchasing an additional 100 shares during the last quarter. Rice Hall James & Associates LLC boosted its holdings in Mesa Laboratories by 25.1% in the fourth quarter. Rice Hall James & Associates LLC now owns 27,668 shares of the medical instruments supplier's stock worth $3,649,000 after purchasing an additional 5,560 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Mesa Laboratories by 9.3% in the fourth quarter. Principal Financial Group Inc. now owns 38,359 shares of the medical instruments supplier's stock worth $5,058,000 after purchasing an additional 3,252 shares during the last quarter. Finally, Choreo LLC boosted its holdings in Mesa Laboratories by 38.0% in the fourth quarter. Choreo LLC now owns 5,052 shares of the medical instruments supplier's stock worth $667,000 after purchasing an additional 1,392 shares during the last quarter. 90.60% of the stock is owned by institutional investors.
Mesa Laboratories Stock Down 0.9 %
MLAB opened at $122.33 on Friday. The company has a current ratio of 0.71, a quick ratio of 0.53 and a debt-to-equity ratio of 0.61. Mesa Laboratories, Inc. has a 1-year low of $83.68 and a 1-year high of $155.12. The company has a market capitalization of $664.74 million, a PE ratio of -2.64 and a beta of 0.82. The firm's 50 day simple moving average is $139.82 and its two-hundred day simple moving average is $129.57.
Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.41 by $0.66. Mesa Laboratories had a negative net margin of 104.92% and a positive return on equity of 30.23%. As a group, equities analysts forecast that Mesa Laboratories, Inc. will post 8 EPS for the current year.
Mesa Laboratories Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Monday, March 17th. Shareholders of record on Friday, February 28th will be issued a $0.16 dividend. The ex-dividend date is Friday, February 28th. This represents a $0.64 dividend on an annualized basis and a yield of 0.52%. Mesa Laboratories's dividend payout ratio is currently -1.38%.
About Mesa Laboratories
(
Free Report)
Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mesa Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.
While Mesa Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
